Preclinical drug development for childhood cancer

Author： Moreno Lucas   Chesler Louis   Hargrave Darren   Eccles Suzanne A   Pearson Andrew DJ  

Publisher： Informa Healthcare

ISSN： 1746-0441

Source： Expert Opinion on Drug Discovery, Vol.6, Iss.1, 2011-01, pp. : 49-64

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Metabonomics in preclinical drug development

By Robertson Donald G   Reily Michael D   Baker J David  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 1, Iss. 3, 2005-10 ,pp. : 363-376

Informa Healthcare

Access to resources Recommend Favorite

A Review of: "Preclinical Drug Development"

By Keep Marcus F.  

Drug Development and Industrial Pharmacy, Vol. 33, Iss. 4, 2007-04 ,pp. : 493-493

Informa Healthcare

Access to resources Recommend Favorite

In Vivo Models of Childhood Leukemia for Preclinical Drug Testing

By  

Current Drug Targets, Vol. 8, Iss. 6, 2007-06 ,pp. : 773-783

Bentham Science Publishers

Access to resources Recommend Favorite

Recent advances in preclinical drug development in multiple sclerosis

By Hoban C.J.  

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 7, 1998-07 ,pp. : 831-854

Informa Healthcare

Access to resources Recommend Favorite

Positron Emitting Tracers in Pre-Clinical Drug Development

By  

Current Radiopharmaceuticals, Vol. 5, Iss. 2, 2012-04 ,pp. : 90-98

Bentham Science Publishers

Access to resources Recommend Favorite